CARsgen Therapeutics Holdings Limited: Completion of Share Placing and Top-Up Subscription
Hong Kong, May 26, 2026 – CARsgen Therapeutics Holdings Limited (Stock Code: 2171) has announced the successful completion of a significant equity transaction, which includes the placing of existing shares and a top-up subscription of new shares under a general mandate. This development is likely to be of considerable interest to investors, as it involves a material change in the capital structure and brings in substantial new funding for the company.
Key Points of the Announcement
- Placing Completion: On May 19, 2026, a total of 23,700,000 existing shares were placed by joint placing agents at a price of HK\$19.84 per share to at least six independent placees. All placees and their ultimate beneficial owners are confirmed as Independent Third Parties and are not acting in concert with the vendor.
- Top-Up Subscription: After all necessary conditions were met, including the waiver under Note 6 of Rule 26 of the Takeovers Code, 23,700,000 new shares were allotted and issued to the vendor at the same price per share (HK\$19.84) on May 26, 2026.
- Gross and Net Proceeds: The company raised gross proceeds of approximately HK\$470.2 million and net proceeds of about HK\$462 million after deducting relevant fees and expenses. The net subscription price comes to roughly HK\$19.49 per share.
- Intended Use of Proceeds:
- 70% (approx. HK\$323.37 million) will be allocated to global clinical development of the company’s innovative drugs, including projects in China.
- 15% (approx. HK\$69.29 million) will be directed toward equipment and facility expenses for global R&D and manufacturing, including new process development.
- The remaining 15% (approx. HK\$69.29 million) is earmarked for working capital and other general corporate purposes.
- Shareholding Structure Impact:
- Before the transaction, the vendor held 34.70% of shares. After the placing (but before subscription), the vendor’s stake dropped to 30.55%. Following the subscription, the vendor’s holding returns to 33.32%.
- Concert parties, including related entities and persons, will together hold 36.59% of the company’s issued shares after the transaction.
- The total number of issued shares has increased from 570,942,748 to 594,642,748.
Price-Sensitive and Shareholder-Relevant Details
- Significant Capital Injection: The successful raising of over HK\$460 million in net proceeds provides CARsgen with strong financial resources to continue its global R&D and clinical development activities. This can potentially accelerate the company’s growth, increase its competitiveness, and support the commercialization of its innovative drug pipeline.
- Share Dilution: Existing shareholders should note the dilution effect, as the total number of shares has increased by approximately 4.2% (from 570.9 million to 594.6 million). This may impact per-share metrics in the short term, but is offset by the increased capital for business expansion.
- Change in Major Shareholder Holdings: The placing followed by a top-up subscription is a method to maintain the principal shareholder’s stake while introducing new investors. This structure is often seen as supportive of both liquidity and long-term shareholder alignment.
- Strategic Use of Funds: The clear allocation of proceeds towards clinical development, R&D infrastructure, and working capital may reassure investors regarding the company’s focus and prudent financial management. The timeline for full utilization of funds extends to the end of 2028 for most categories, indicating long-term planning.
- Regulatory Considerations: The company obtained necessary waivers under the Takeovers Code, ensuring compliance and avoiding triggering mandatory general offers.
Additional Shareholder Information
- The vendor is a consortium owned by a group of founders, executives, and related parties, who collectively entered into a concert party agreement ensuring aligned interests.
- The shareholding figures do not include unvested restricted share units or unexercised share options, suggesting potential further dilution if these are exercised in the future.
Conclusion: This transaction is a major event for CARsgen Therapeutics, significantly enhancing its financial position and strengthening its ability to execute on its R&D and commercialization strategies. The structure of the deal ensures that major shareholders remain committed, while bringing in new institutional or sophisticated investors. These factors, combined with the clear use of proceeds, are likely to be viewed positively by the market and could have a material impact on the company’s share price.
Disclaimer
This article is for informational purposes only and does not constitute investment advice or an offer to sell or solicit an offer to buy any securities. Investors are advised to consult their own professional advisers before making any investment decision. The information herein is based on public disclosures and may be subject to change. The author and publisher accept no responsibility for any loss arising from reliance on this article.
CARsgen Therapeutics Holdings Limited：完成股份配售及增發重要通告
香港，2026年5月26日 – CARsgen Therapeutics Holdings Limited（股份代號：2171）宣佈已成功完成一項重大股本交易，包括現有股份配售及根據一般授權增發新股份。這次動作涉及公司資本結構的重大變動，並為公司帶來可觀的新資金，對投資者極具參考價值。
公告重點摘要
- 配售完成：於2026年5月19日，共有23,700,000股現有股份以每股HK\$19.84的價格，經聯席配售代理以盡力基準方式配售予不少於六名獨立第三方投資者。所有配售對象及其最終實益擁有人均為獨立第三方，並非與賣方一致行動。
- 增發新股：所有相關條件（包括《收購守則》第26條的豁免）已獲達成後，公司於2026年5月26日以相同價格（每股HK\$19.84）向賣方增發23,700,000股新股份。
- 集資金額：公司從增發集資總額約為HK\$4.7億，扣除相關開支後，淨收益約為HK\$4.62億，淨增發價格約為每股HK\$19.49。
- 資金用途：
- 70%（約HK\$3.23億）將用於公司創新藥物的全球（包括中國）臨床開發。
- 15%（約HK\$6,929萬）將投放於全球研發和生產設施及設備開支，包括新流程開發。
- 其餘15%（約HK\$6,929萬）作為營運資金及其他一般企業用途。
- 股份結構變動：
- 交易前賣方持股為34.70%；配售後（但增發前）降至30.55%；完成配售及增發後回升至33.32%。
- 賣方及其一致行動人合計於交易後持有約36.59%的公司股份。
- 公司已發行股份總數由570,942,748股增至594,642,748股。
對股東具影響及可能影響股價的重要資訊
- 大量資金融入：成功融資逾4.6億港元，為公司全球研發及臨床發展提供充足資金，有助加速增長及創新藥管線商業化，提升競爭力。
- 股份攤薄：現有股東需注意股份總數增加約4.2%，短期內或影響每股財務指標，但長遠受益於業務擴展帶來的增長動力。
- 主要股東持股變動：配售加增發的結構，有助維持主要股東持股穩定，同時引入新資金及投資者，有利股份流動性及長線價值。
- 資金用途明確：資金分配及預期使用時間表清晰，最遲至2028年底前全面動用，反映公司長遠規劃及審慎管理。
- 監管合規：公司已獲取所有必要豁免，確保合規經營，避免觸發強制要約收購。
其他股東須知
- 賣方為創辦人及高管組成的財團，與相關人士簽署一致行動協議，確保利益一致。
- 股份數據未包括尚未歸屬的受限制股份單位及未行使的期權，未來如獲行使或會進一步攤薄現有持股。
總結：這次交易為CARsgen帶來重大財務增強，支持其全球研發及商業化戰略。交易結構兼顧主要股東穩定及引入新資金，有望獲市場正面看待，或對公司股價帶來實質影響。
免責聲明
本文章僅供參考，並不構成任何投資建議或邀請出售／購買任何證券。投資者應諮詢專業顧問後作出投資決定。本文基於公開資訊撰寫，如有更改恕不另行通知。作者及出版人對因本文內容而引致的任何損失概不負責。
